TY - JOUR
T1 - Gene delivery nanoparticles to modulate angiogenesis
AU - Kim, Jayoung
AU - Mirando, Adam C.
AU - Popel, Aleksander S.
AU - Green, Jordan J.
N1 - Funding Information:
This work was supported by the National Institutes of Health [ R01EB016721 , R01HL101200 , R21EY026148 and R01CA138264 ] and a Samsung Scholarship to JK.
Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2017/9/15
Y1 - 2017/9/15
N2 - Angiogenesis is naturally balanced by many pro- and anti-angiogenic factors while an imbalance of these factors leads to aberrant angiogenesis, which is closely associated with many diseases. Gene therapy has become a promising strategy for the treatment of such a disordered state through the introduction of exogenous nucleic acids that express or silence the target agents, thereby engineering neovascularization in both directions. Numerous non-viral gene delivery nanoparticles have been investigated towards this goal, but their clinical translation has been hampered by issues associated with safety, delivery efficiency, and therapeutic effect. This review summarizes key factors targeted for therapeutic angiogenesis and anti-angiogenesis gene therapy, non-viral nanoparticle-mediated approaches to gene delivery, and recent gene therapy applications in pre-clinical and clinical trials for ischemia, tissue regeneration, cancer, and wet age-related macular degeneration. Enhanced nanoparticle design strategies are also proposed to further improve the efficacy of gene delivery nanoparticles to modulate angiogenesis.
AB - Angiogenesis is naturally balanced by many pro- and anti-angiogenic factors while an imbalance of these factors leads to aberrant angiogenesis, which is closely associated with many diseases. Gene therapy has become a promising strategy for the treatment of such a disordered state through the introduction of exogenous nucleic acids that express or silence the target agents, thereby engineering neovascularization in both directions. Numerous non-viral gene delivery nanoparticles have been investigated towards this goal, but their clinical translation has been hampered by issues associated with safety, delivery efficiency, and therapeutic effect. This review summarizes key factors targeted for therapeutic angiogenesis and anti-angiogenesis gene therapy, non-viral nanoparticle-mediated approaches to gene delivery, and recent gene therapy applications in pre-clinical and clinical trials for ischemia, tissue regeneration, cancer, and wet age-related macular degeneration. Enhanced nanoparticle design strategies are also proposed to further improve the efficacy of gene delivery nanoparticles to modulate angiogenesis.
KW - Age-related macular degeneration
KW - Gene therapy
KW - Ischemia
KW - Non-viral
KW - Polymeric nanoparticles
KW - Tissue engineering
KW - Tumor
KW - Wound healing
UR - http://www.scopus.com/inward/record.url?scp=85008147852&partnerID=8YFLogxK
U2 - 10.1016/j.addr.2016.11.003
DO - 10.1016/j.addr.2016.11.003
M3 - Review article
C2 - 27913120
AN - SCOPUS:85008147852
SN - 0169-409X
VL - 119
SP - 20
EP - 43
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
ER -